Puma Biotechnology Inc (PBYI): Market Capitalization-to-Revenue Ratio

Puma Biotechnology revenues rely on the sales of its oncology drug and patent expiration dates. The market cap-to-revenue ratio confirms this trend, where the value of 1.80 describes the current level. The protection of Nerlynx deters competitors, although pressure from new treatment methods is increasing. High brand authority in breast cancer therapy ensures the trust of physicians and patients.

Puma Biotechnology's reliance on external CMO manufacturing sites increases the risk of operational disruptions, making the assessment of market expectations via the price-to-sales ratio critical. By analyzing the P/S multiple trend on GURU.Markets, an investor determines the value of each dollar of sales, identifying asset overvaluation or potential business undervaluation compared to industry averages.